The deal marks the complete exit of Morphosis Capital and founders from DocProcess.
“This deal marks the start of a new stage for DocProcess together with AGENA3000, an organization that shares our vision for the future of digitalization. We also want to thank Morphosis Capital for believing in us and supporting the company’s development,” stated Daniela and Liviu Apolozan.
The acquisition by AGENA3000 offers DocProcess the opportunity to step up international expansion and tap into the enterprise segment.
The deal marks the second complete exit of Morphosis Capital Fund I, after the sale of the entire stake held in Clinicile Dentare Dr. Leahu to Regina Maria, in June 2023.
(English version by Catalina Apostoiu)